转移性去势抵抗性前列腺癌患者经放射性核素治疗后继发药物性肝损伤一例。

IF 0.5 Q4 GASTROENTEROLOGY & HEPATOLOGY

ACG Case Reports Journal Pub Date : 2025-09-29 eCollection Date: 2025-10-01 DOI:10.14309/crj.0000000000001845

Brian T Lee, Ravi J Kankotia, David Braxton

{"title":"转移性去势抵抗性前列腺癌患者经放射性核素治疗后继发药物性肝损伤一例。","authors":"Brian T Lee, Ravi J Kankotia, David Braxton","doi":"10.14309/crj.0000000000001845","DOIUrl":null,"url":null,"abstract":"Lutetium-177 vipivotide tetraxetan (LuPSMA) is a small molecule inhibitor with high affinity to prostate-specific membrane antigen and is currently used in the treatment of metastatic castrate-resistant prostate cancer. Hepatotoxicity has seldom been reported. This is a case of drug-induced liver injury presenting in a patient who received 5 cycles of LuPSMA for metastatic castrate-resistant prostate cancer. In this report, we provide a probable case of drug-induced liver injury with imaging and histologic findings of cholestatic liver injury and stricturing cholangiopathy related to LuPSMA. This is the first report of LuPSMA as a probable cause of hepatotoxicity.","PeriodicalId":7394,"journal":{"name":"ACG Case Reports Journal","volume":"12 10","pages":"e01845"},"PeriodicalIF":0.5000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479103/pdf/","citationCount":"0","resultStr":"{\"title\":\"Drug-Induced Liver Injury Secondary to Radionuclide Therapy With Lutetium-177 Vipivotide Tetraxetan in a Patient With Metastatic Castrate-Resistant Prostate Cancer.\",\"authors\":\"Brian T Lee, Ravi J Kankotia, David Braxton\",\"doi\":\"10.14309/crj.0000000000001845\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lutetium-177 vipivotide tetraxetan (LuPSMA) is a small molecule inhibitor with high affinity to prostate-specific membrane antigen and is currently used in the treatment of metastatic castrate-resistant prostate cancer. Hepatotoxicity has seldom been reported. This is a case of drug-induced liver injury presenting in a patient who received 5 cycles of LuPSMA for metastatic castrate-resistant prostate cancer. In this report, we provide a probable case of drug-induced liver injury with imaging and histologic findings of cholestatic liver injury and stricturing cholangiopathy related to LuPSMA. This is the first report of LuPSMA as a probable cause of hepatotoxicity.\",\"PeriodicalId\":7394,\"journal\":{\"name\":\"ACG Case Reports Journal\",\"volume\":\"12 10\",\"pages\":\"e01845\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479103/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACG Case Reports Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/crj.0000000000001845\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACG Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/crj.0000000000001845","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Lutetium-177 vipivotide tetraxetan （LuPSMA）是一种对前列腺特异性膜抗原具有高亲和力的小分子抑制剂，目前用于治疗转移性去势抵抗性前列腺癌。肝毒性很少被报道。这是一个药物性肝损伤的病例，患者接受了5个周期的LuPSMA治疗转移性去势抵抗性前列腺癌。在本报告中，我们提供了一个可能的药物性肝损伤病例，其影像学和组织学表现为与LuPSMA相关的胆汁淤积性肝损伤和狭窄性胆管病。这是首次报道LuPSMA作为肝毒性的可能原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Drug-Induced Liver Injury Secondary to Radionuclide Therapy With Lutetium-177 Vipivotide Tetraxetan in a Patient With Metastatic Castrate-Resistant Prostate Cancer.

Lutetium-177 vipivotide tetraxetan (LuPSMA) is a small molecule inhibitor with high affinity to prostate-specific membrane antigen and is currently used in the treatment of metastatic castrate-resistant prostate cancer. Hepatotoxicity has seldom been reported. This is a case of drug-induced liver injury presenting in a patient who received 5 cycles of LuPSMA for metastatic castrate-resistant prostate cancer. In this report, we provide a probable case of drug-induced liver injury with imaging and histologic findings of cholestatic liver injury and stricturing cholangiopathy related to LuPSMA. This is the first report of LuPSMA as a probable cause of hepatotoxicity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACG Case Reports Journal GASTROENTEROLOGY & HEPATOLOGY-

自引率

14.30%

发文量

170

审稿时长

12 weeks

期刊介绍： ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.